Cargando…

Management of uterine sarcomas and prognostic indicators: real world data from a single-institution

BACKGROUND: Uterine sarcomas consist a heterogeneous group of mesenchymal gynecological malignancies with unclear therapeutic recommendations and unspecific but poor prognosis, since they usually metastasize and tend to recur very often, even in early stages. METHODS: We retrospectively analyzed all...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyriazoglou, Anastasios, Liontos, Michael, C Ziogas, Dimitrios, Zagouri, Flora, Koutsoukos, Kostantinos, Tsironis, Giorgos, Tsiara, Anna, Kaparelou, Maria, Zakopoulou, Roubini, Thomakos, Nikolaos, Haidopoulos, Dimitrios, Papaspyrou, Irene, Rodolakis, Alexandros, Bamias, Aristotelis, Dimopoulos, Meletios Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292121/
https://www.ncbi.nlm.nih.gov/pubmed/30541504
http://dx.doi.org/10.1186/s12885-018-5156-1
Descripción
Sumario:BACKGROUND: Uterine sarcomas consist a heterogeneous group of mesenchymal gynecological malignancies with unclear therapeutic recommendations and unspecific but poor prognosis, since they usually metastasize and tend to recur very often, even in early stages. METHODS: We retrospectively analyzed all female patients with uterine sarcomas treated in our institution over the last 17 years. Clinico-pathological data, treatments and outcomes were recorded. Kaplan-Meier curves were plotted and time-to-event analyses were estimated using Cox regression. RESULTS: Data were retrieved from 61 women with a median age of 53 (range: 27–78) years, at diagnosis. Fifty-one patients were diagnosed with leiomyosarcoma (LMS), 3 with high grade endometrial stromal sarcoma (ESS), 5 with undifferentiated uterine sarcoma (UUS), 1 with Ewing sarcoma (ES) and 1 with Rhabdomyosarcoma (RS). 24 cases had stage I, 7 stage II, 14 stage III and 16 stage IV disease. Median disease-free survival (DFS) in adjuvant approach was 18.83 months, and median overall survival (OS) 31.07 months. High mitotic count (> 15 mitoses) was significantly associated with worse OS (P < 0.001) and worse DFS (P = 0.028). CONCLUSIONS: Mitotic count appears to be independent prognostic factor while further insights are needed to improve adjuvant and palliative treatment of uterine sarcomas.